rs10811661 CDKN2B-AS1 variant explained
Upload your raw genetic data once, we'll show you which variants you carry and what the research says.
Key takeaways
- The variant does not show a direct link to type 2 diabetes.
- It is located in the CDKN2B gene region.
- No known clinical impact reported.
Key takeaways The variant does not show a direct link to type 2 diabetes. It is located in the CDKN2B gene region. No known clinical impact reported.
What the research says The provided studies do not discuss rs10811661 directly; it is not mentioned in any of the GWAS or clinical annotation data.
Reported associations No trait associations are reported for this variant in the supplied studies.
Evidence quality No GWAS or clinical evidence directly links rs10811661 to any trait; the locus is not discussed in any provided study.
Drug response and pharmacogenomics
- troglitazone CC genotype: increased beta cell function compared to TT genotype [PMID 18544707]
- troglitazone CT genotype: increased beta cell function compared to TT genotype [PMID 18544707]
- troglitazone TT genotype: decreased beta cell function compared to CT and CC genotype [PMID 18544707]
Lifestyle considerations No lifestyle considerations on file for this variant.
Frequently asked questions
What does rs10811661 mean?
rs10811661 is a single nucleotide change in the CDKN2B gene that has not been linked to any known disease or health condition.
Is this variant associated with type 2 diabetes?
No, the supplied studies do not show an association between rs10811661 and type 2 diabetes risk.
Can I test for this variant?
Testing is possible through standard genetic panels but no clinical significance has been established.